News & Events

July 30, 2008: Medgenics Granted Approval: to Commence Its Landmark Phase I/II Clinical Study of EPODURE to treat Anemia April 14, 2008: Research Update: Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned Mar 18, 2008: Medgenics consolidates corporate and R&D operations into new office facility Feb 1, 2008: Lord Steinberg Appointment, Medgenics (AIM: MEDG), the US incorporated biopharmaceutical company that was admitted to AIM in December 2007, is pleased to announce... Dec 4, 2007: ADMISSION TO TRADING Karmiel, Israel and London, UK – 4 December, 2007 – Medgenics (AIM: MEDG), the US incorporated holding company of a biopharmaceutical group, is pleased to announce... Nov 29, 2007: Medgenics raises £3.28 Million in initial public offering in conjunction with forthcoming listing on AIM Karmiel, Israel and London, UK - 29 November, 2007 - Medgenics, Inc., a US biopharmaceutical company with key operations in Israel... Nov 1, 2006: Medgenics To Present At Rodman & Renshaw 8th Annual Healthcare Conference CEO to Share Clinical Proof of Principle and Development Strategy